Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial
Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference0.5%

- Check26 days agoChange Detected- Removed multiple MedlinePlus topics: Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, and Substandard Drugs. - Added a new Revision tag: v3.1.0. Overall, core topic coverage is reduced with a version update.SummaryDifference0.1%

- Check40 days agoChange DetectedVersion bumped to v3.0.2 with a new Informed Consent Form and time-stamped updates; older status/dates and navigation anchor removed.SummaryDifference0.2%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.0%

- Check55 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as a comprehensive list of pharmaceutical terms related to drug safety and immunology. The revision version has also been updated from v2.16.12 to v3.0.0.SummaryDifference0.5%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%

Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.